These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 31779574)

  • 1. Using information on ART costs and benefits to mobilise resources - comparing different methods and contexts.
    Kinghorn A
    Afr J AIDS Res; 2019 Dec; 18(4):289-296. PubMed ID: 31779574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost effectiveness analysis of clinically driven versus routine laboratory monitoring of antiretroviral therapy in Uganda and Zimbabwe.
    Medina Lara A; Kigozi J; Amurwon J; Muchabaiwa L; Nyanzi Wakaholi B; Mujica Mota RE; Walker AS; Kasirye R; Ssali F; Reid A; Grosskurth H; Babiker AG; Kityo C; Katabira E; Munderi P; Mugyenyi P; Hakim J; Darbyshire J; Gibb DM; Gilks CF;
    PLoS One; 2012; 7(4):e33672. PubMed ID: 22545079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cost effectiveness of combination antiretroviral therapy for HIV disease.
    Freedberg KA; Losina E; Weinstein MC; Paltiel AD; Cohen CJ; Seage GR; Craven DE; Zhang H; Kimmel AD; Goldie SJ
    N Engl J Med; 2001 Mar; 344(11):824-31. PubMed ID: 11248160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reflecting the Health Opportunity Costs of Funding Decisions Within Value Frameworks: Initial Estimates and the Need for Further Research.
    Ochalek J; Lomas J
    Clin Ther; 2020 Jan; 42(1):44-59.e2. PubMed ID: 31955967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unit costs for delivery of antiretroviral treatment and prevention of mother-to-child transmission of HIV: a systematic review for low- and middle-income countries.
    Galárraga O; Wirtz VJ; Figueroa-Lara A; Santa-Ana-Tellez Y; Coulibaly I; Viisainen K; Medina-Lara A; Korenromp EL
    Pharmacoeconomics; 2011 Jul; 29(7):579-99. PubMed ID: 21671687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost implications of HIV retesting for verification in Africa.
    Lasry A; Kalou MB; Young PR; Rurangirwa J; Parekh B; Behel S
    PLoS One; 2019; 14(7):e0218936. PubMed ID: 31260467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does directly administered antiretroviral therapy represent good value for money in sub-Saharan Africa? A cost-utility and value of information analysis.
    Uthman RT; Sutton AJ; Jackson LJ; Uthman OA
    PLoS One; 2018; 13(1):e0191465. PubMed ID: 29360841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The economics of effective AIDS treatment in Thailand.
    Over M; Revenga A; Masaki E; Peerapatanapokin W; Gold J; Tangcharoensathien V; Thanprasertsuk S
    AIDS; 2007 Jul; 21 Suppl 4():S105-16. PubMed ID: 17620745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of antiretroviral therapy for prevention.
    Kahn JG; Marseille EA; Bennett R; Williams BG; Granich R
    Curr HIV Res; 2011 Sep; 9(6):405-15. PubMed ID: 21999776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy.
    Freedberg KA; Kumarasamy N; Losina E; Cecelia AJ; Scott CA; Divi N; Flanigan TP; Lu Z; Weinstein MC; Wang B; Ganesh AK; Bender MA; Mayer KH; Walensky RP
    AIDS; 2007 Jul; 21 Suppl 4(Suppl 4):S117-28. PubMed ID: 17620747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economics of switching to second-line antiretroviral therapy with lopinavir/ritonavir in Africa: estimates based on DART trial results and costs for Uganda and Kenya.
    Simpson KN; Baran RW; Kirbach SE; Dietz B
    Value Health; 2011 Dec; 14(8):1048-54. PubMed ID: 22152173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic evaluation of weekends-off antiretroviral therapy for young people in 11 countries.
    Tierrablanca LE; Ochalek J; Ford D; Babiker A; Gibb D; Butler K; Turkova A; Griffin S; Revill P;
    Medicine (Baltimore); 2018 Feb; 97(5):e9698. PubMed ID: 29384848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective evaluation of the cost effectiveness of adding lamivudine to zidovudine-containing antiretroviral treatment regimens in HIV infection. European perspective.
    Lacey L; Youle M; Trueman P; Staszewski S; Schrappe M; Behrens M
    Pharmacoeconomics; 1999; 15 Suppl 1():39-53. PubMed ID: 10537441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of screening for HIV in primary care: a health economics modelling analysis.
    Baggaley RF; Irvine MA; Leber W; Cambiano V; Figueroa J; McMullen H; Anderson J; Santos AC; Terris-Prestholt F; Miners A; Hollingsworth TD; Griffiths CJ
    Lancet HIV; 2017 Oct; 4(10):e465-e474. PubMed ID: 28768604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Scaling up of HIV treatment for men who have sex with men in Bangkok: a modelling and costing study.
    Zhang L; Phanuphak N; Henderson K; Nonenoy S; Srikaew S; Shattock AJ; Kerr CC; Omune B; van Griensven F; Osornprasop S; Oelrichs R; Ananworanich J; Wilson DP
    Lancet HIV; 2015 May; 2(5):e200-7. PubMed ID: 26423002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. National and provincial estimated costs and cost effectiveness of a programme to reduce mother-to-child HIV transmission in South Africa.
    Wilkinson D; Floyd K; Gilks CF
    S Afr Med J; 2000 Aug; 90(8):794-8. PubMed ID: 11022629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Laboratory Monitoring of Antiretroviral Therapy for HIV Infection: Cost-Effectiveness and Budget Impact of Current and Novel Strategies.
    Ouattara EN; Robine M; Eholié SP; MacLean RL; Moh R; Losina E; Gabillard D; Paltiel AD; Danel C; Walensky RP; Anglaret X; Freedberg KA
    Clin Infect Dis; 2016 Jun; 62(11):1454-1462. PubMed ID: 26936666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cost of providing comprehensive HIV treatment in PEPFAR-supported programs.
    Menzies NA; Berruti AA; Berzon R; Filler S; Ferris R; Ellerbrock TV; Blandford JM
    AIDS; 2011 Sep; 25(14):1753-60. PubMed ID: 21412127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research.
    Woods B; Revill P; Sculpher M; Claxton K
    Value Health; 2016 Dec; 19(8):929-935. PubMed ID: 27987642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of chemoprophylaxis after occupational exposure to HIV.
    Pinkerton SD; Holtgrave DR; Pinkerton HJ
    Arch Intern Med; 1997 Sep; 157(17):1972-80. PubMed ID: 9308509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.